

**S5 Table.** Survival rate of NWRT by stage

|           | RCC    |            | CCSK   |            | MRTK   |            | CMN    |            | Others |            |
|-----------|--------|------------|--------|------------|--------|------------|--------|------------|--------|------------|
|           | 5-Year |            | 5-Year |            | 5-Year |            | 5-Year |            | 5-Year |            |
|           | No.    | OS/EFS (%) | No.    | OS/EFS (%) | No.    | OS/EFS (%) | No.    | OS/EFS (%) | No.    | OS/EFS (%) |
| Overall   | 36     | 90.6/82.1  | 24     | 81.1/63.6  | 16     | 60.3/56.2  | 12     | 100/91.7   | 9      | 100/87.5   |
| Stage I   | 14     | 100/90.9   | 5      | 100/60.0   | 3      | 100/66.7   | 2      | 100/100    | 1      | 100/100    |
| Stage II  | 5      | 100/100    | 7      | 100/100    | 5      | 80.0/80.0  | 0      | NA         | 2      | 100/100    |
| Stage III | 9      | 100/88.9   | 6      | 100/50.0   | 2      | 100/100    | 0      | NA         | 3      | 100/66.7   |
| Stage IV  | 8      | 60.0/50.0  | 5      | 40.0/40.0  | 5      | 16.7/16.7  | 2      | 100/NA     | 1      | 100/100    |
| Stage V   | 0      |            | 1      | NA         | 1      | NA         | 0      |            | 0      |            |
| NA        | 0      |            | 0      |            | 0      |            | 8      |            | 2      |            |

CCSK, clear cell sarcoma of the kidney; CMN, congenital mesoblastic nephroma; OS/EFS, overall survival/vent-free survival; MRTK, malignant rhabdoid tumor of the kidney; NA, not assessable; NWRT, non-Wilms renal tumors; RCC, renal cell carcinoma; NA, not assessable.

### Reference

1. Dome JS, Graf N, Geller JI, Fernandez CV, Mullen EA, Spreafico F, et al. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. *J Clin Oncol.* 2015;33:2999-3007.